Noven Pharma takes over Daytrana transdermal system from Shire
The Daytrana patch is a prescription central nervous system (brain) stimulant medicine used to treat ADHD in children 6 to 17 years old. Daytrana will be marketed and
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Jevtana, a microtubule inhibitor, is approved in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-based treatment regimen.